SCHEMBL895236

SCHEMBL895236

CCOP(=O)(OCC)c1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
TDP1 Q9NUW8 1/20 0.43
KDM4E B2RXH2 2/20 0.43
UTRN P46939 1/20 0.42
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA9 Q16790 2/20 0.40
CA4 P22748 1/20 0.40
CA5A P35218 1/20 0.40
CA7 P43166 1/20 0.40
CA5B Q9Y2D0 1/20 0.40
LMNA P02545 2/20 0.39
GAA P10253 1/20 0.39
CCNT1 O60563 1/20 0.39
CDK9 P50750 1/20 0.39
POLB P06746 1/20 0.39
HTR2A P28223 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL578264 0.91 ALDH1A1 (0.46) ALDH1A1TDP1KDM4EUTRNKMT2A
SCHEMBL6829825 0.89 TDP1 (0.49) TDP1KMT2AMEN1CA12CA1
SCHEMBL4580177 0.88 ALDH1A1 (0.43) ALDH1A1KDM4EKMT2AMEN1LMNA
SCHEMBL779299 0.83 ALDH1A1 (0.47) ALDH1A1KDM4EUTRNKMT2AMEN1
SCHEMBL9407115 0.83 TDP1 (0.45) TDP1KMT2AMEN1CA12CA1
SCHEMBL107781 0.81 HPGD (0.48) ALDH1A1TDP1KDM4EKMT2AMEN1
SCHEMBL12229756 0.80 ALDH1A1 (0.49) ALDH1A1KDM4EUTRNKMT2AMEN1
SCHEMBL23057071 0.79 TDP1 (0.43) TDP1KMT2AMEN1CA12CA1
SCHEMBL11140840 0.79 POLB (0.54) ALDH1A1TDP1KMT2AMEN1CA12
SCHEMBL13637001 0.79 TDP1 (0.43) TDP1KMT2AMEN1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116425794-A Aryl phosphonate compound and preparation method thereof 烟台大学 2023-07-14 CN disclosed
US-8846978-B2 Electronic devices comprising novel phosphonic acid surface modifiers IMPERIAL INNOVATIONS LTD. (GB) 2014-09-30 US disclosed
US-8586208-B2 Stable electrodes with modified work functions and methods for organic electronic devices GEORGIA TECH RESEARCH CORPORATION (US) 2013-11-19 US disclosed
US-20120114974-A1 ELECTRONIC DEVICES COMPRISING NOVEL PHOSPHONIC ACID SURFACE MODIFIERS NATIONAL SCIENCE FOUNDATION 2012-05-10 US disclosed
US-20120108547-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF PHARMACYCLICS, INC. (US) 2012-05-03 US disclosed
US-20120101065-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF PHARMACYCLICS, INC. (US) 2012-04-26 US disclosed
US-20120083470-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF PHARMACYCLICS, INC. (US) 2012-04-05 US disclosed
US-8067395-B2 Inhibitors of tyrosine kinases and uses thereof PHARMACYCLICS, INC. (US) 2011-11-29 US disclosed
US-8044091-B2 Phospho-indoles as HIV inhibitors IDENIX PHARMACEUTICALS, INC. (US) 2011-10-25 US disclosed
US-8044091-B2 Phospho-indoles as HIV inhibitors IDENIX PHARMACEUTICALS, INC. (US) 2011-10-25 US disclosed
US-7534809-B2 Phospho-indoles as HIV inhibitors IDENIX PHARMACEUTICALS, INC. (US) 2009-05-19 US disclosed
EP-1799696-B1 PHOSPHOINDOLES AS HIV INHIBITORS IDENIX PHARMACEUTICALS INC (US) 2008-11-12 EP disclosed
EP-1981888-A2 INHIBITORS OF TYROSINE KINASES AND USES THEREOF Pharmacyclics, Inc. (US) 2008-10-22 EP disclosed
EP-1961757-A1 Phosphoindoles as HIV inhibitors IDENIX Pharmaceuticals, Inc. (US) 2008-08-27 EP disclosed
US-20080039426-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF PHARMACYCLICS, INC. (US) 2008-02-14 US disclosed
WO-2007087068-A2 INHIBITORS OF TYROSINE KINASES AND USES THEREOF PHARMACYCLICS, INC. (US) 2007-08-02 WO disclosed
EP-0807637-B1 Process for the preparation of tertiary phosphanes containing phosphinate or phosphonate groups and novel tertiary phosphanes containing phosphinate groups CELANESE CHEM EUROPE GMBH (DE) 2002-02-13 EP disclosed
WO-2001096349-A1 WATER SOLUBLE PHOSPHINES THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2001-12-20 WO disclosed
US-5801263-A Process for preparing tertiary phosphines containing phosphinate or phosphonate groups, and novel tertiary phosphines containing phosphinate groups HOECHST AKTIENGESELLSCHAFT (DE) 1998-09-01 US disclosed
EP-0807637-A1 Process for the preparation of tertiary phosphanes containing phosphinate or phosphonate groups and novel tertiary phosphanes containing phosphinate groups HOECHST AKTIENGESELLSCHAFT (DE) 1997-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108547-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF LCK, ABL1, SRC ALDH1A1 2984/4885TDP1 557/4885KDM4E 2460/4885
US-20120083470-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF LCK, ABL1, SRC ALDH1A1 2984/4885TDP1 557/4885KDM4E 2460/4885
US-20120114974-A1 ELECTRONIC DEVICES COMPRISING NOVEL PHOSPHONIC ACID SURFACE MODIFIERS EFNA1, PHOSPHO1, EPHA6 ALDH1A1 2641/4885TDP1 1434/4885KDM4E 1389/4885
US-20080039426-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF LCK, ABL1, SRC ALDH1A1 2984/4885TDP1 557/4885KDM4E 2460/4885
US-20120101065-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF LCK, ABL1, SRC ALDH1A1 2984/4885TDP1 557/4885KDM4E 2460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.